| Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis K Drellia, L Kokoti, CI Deligianni, D Papadopoulos, DD Mitsikostas Cephalalgia 41 (7), 851-864, 2021 | 65 | 2021 |
| Headaches in the emergency department–a survey of patients’ characteristics, facts and needs A Doretti, I Shestaritc, D Ungaro, JI Lee, L Lymperopoulos, L Kokoti, ... The journal of headache and pain 20, 1-6, 2019 | 38 | 2019 |
| Placebo and nocebo phenomena in anti-CGRP monoclonal antibody trials for migraine prevention: a meta-analysis L Kokoti, K Drellia, D Papadopoulos, DD Mitsikostas Journal of Neurology 267 (4), 1158-1170, 2020 | 22 | 2020 |
| Latest insights into the pathophysiology of migraine: the ATP-sensitive potassium channels L Kokoti, MAM Al-Karagholi, M Ashina Current Pain and Headache Reports 24, 1-8, 2020 | 20 | 2020 |
| Effect of KATP channel blocker glibenclamide on levcromakalim-induced headache MAM Al-Karagholi, H Ghanizada, L Kokoti, JS Paulsen, JM Hansen, ... Cephalalgia 40 (10), 1045-1054, 2020 | 19 | 2020 |
| Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies J Thuraiaiyah, L Kokoti, MAM Al-Karagholi, M Ashina The Journal of Headache and Pain 23 (1), 43, 2022 | 18 | 2022 |
| Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic L Kokoti, MAM Al-Karagholi, FA Elbahi, H Coskun, H Ghanizada, FM Amin, ... Cephalalgia 42 (9), 846-858, 2022 | 14 | 2022 |
| Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies J Thuraiaiyah, L Kokoti, MAM Al-Karagholi, M Ashina Cephalalgia 42 (8), 781-792, 2022 | 4 | 2022 |
| Cellular senescence correlates with demyelination, brain atrophy and motor impairment in a model of multiple sclerosis (P2. 405) M Karamita, R Nicholas, L Kokoti, S Rizou, DD Mitsikostas, V Gorgoulis, ... Neurology 90 (15_supplement), P2. 405, 2018 | 4 | 2018 |
| Glibenclamide posttreatment does not inhibit levcromakalim induced headache in healthy participants: a randomized clinical trial L Kokoti, MAM Al-Karagholi, CAW Nielsen, M Ashina Neurotherapeutics 20 (2), 389-398, 2023 | 3 | 2023 |
| Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: A randomized clinical trial L Kokoti, MAM Al-Karagholi, ZA Zhuang, S Amirguliyev, FM Amin, ... CEPHALALGIA 43 (1 supp), 205-206, 2023 | | 2023 |
| Investigations of the involvement of different isoforms of KATP channels in headache and migraine pathophysiology L Kokoti | | 2023 |
| Glibenclamide posttreatment does not inhibit levcromakalim induced headache: A randomized clinical trial L Kokoti, MA Al-Karagholi, CA Nielsen, M Ashina JOURNAL OF HEADACHE AND PAIN 23 (SUPPL 1), 2022 | | 2022 |
| Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis (vol 41, pg 851, 2021) K Drellia, L Kokoti, CI Deligianni CEPHALALGIA 42 (1), 90-90, 2022 | | 2022 |
| Placebo And Nocebo Responses In Anti-CGRP Monoclonal Antibody Trials For Migraine Prevention: a meta-analysis L Kokoti, K Drellia, D Papadopoulos, DD Mitsikostas JOURNAL OF HEADACHE AND PAIN 20, 2019 | | 2019 |
Mohammad Al-Mahdi Al-Karagholi, M...Danish Headache Center, Department of Neurology在 regionh.dk 的电子邮件经过验证
